Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 14, 2013

View Archived Issues

Novartis prepares new protein kinase inhibitors

Initial results available from phase I/II study of indibulin in metastatic breast cancer

Iron chelator ameliorates experimental Alzheimer's disease

French scientists design novel DCL enzyme inhibitors

Merck & Co. presents new mGlu2 receptor agonists

U.S. scientists divulge novel cytochrome P450 1A2 inducers

Metabolex presents new GPBA receptor agonists

Novel compounds for autoimmune disorders patented

Ultragenyx inlicenses triheptanoin from Baylor Research Institute

BIKAM Pharmaceuticals prepares new opsin-2 ligands

Esperion's ETC-1002 lowers LDL cholesterol in phase II trial

GeoVax completes enrollment in phase I/II trial for HIV/AIDS vaccine

Dosing completed in phase III BromSite study

Phase II trial of NeoFuse stem cell product meets endpoints

Novel drug-eluting bioadhesive gel reduces inflammation in atherosclerotic plaques in vivo

Morphotek discloses results from phase III study in platinum-sensitive epithelial ovarian cancer

KaloBios begins phase II study of Humaneered PEGylated monoclonal antibody fragment

Topline data reported from phase II study of tivantinib in colorectal cancer

MSD suspends availability of Tredaptive

Evotec advances compound into preclinical development under collaboration with Ono

Mirabegron approved in Europe

European Commission approves use of Zytiga earlier in the treatment cycle

Biota synthesizes promising inhibitor of cell division protein FtsZ

FDA grants orphan drug designation to Telik's investigational treatment for MDS

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...